



Minutes of Annual General Meeting of Shareholders for the year 2025

of

DOD Biotech Public Company Limited

The Annual General Meeting of Shareholders for the year 2025 held on Monday 28 April 2025 at 14:00 hrs. This meeting was streamed live via electronic means from DOD Biotech Public Company Limited's room No.111, Moo 2, Tha Chin Sub-district, Mueang Samutsakhon District, Samut Sakhon 74000,

The meeting started at 14.00 hours.

Mrs. Arpaporn Kosolkul, The Company's Chairman and Chairman of the meeting and there were Directors and the Company's Auditor who participated in the meeting as follows:

The Company's Directors who participated in the meeting

1.	Mrs. Arpaporn Kosolkul	Chairman, Member of the Audit Committee and
		Member of the Nomination and Remuneration Committee
2.	Mr. Dusit Chongsutthanamanee	Independent Director, Vice Chairman, Chairman of the Audit
		Committee, and Chairman of the Nomination and Remuneration
		Committee
3.	Mr. Pongthep Thitapan	Independent Director, Member of the Audit Committee, and
		Member of the Nomination and Remuneration Committee
4.	Dr. Porntep Siriwanarangsun	Independent Director
5.	Mr. Torlarp Chaiyachow	Director and Acting Chief Executive Officer
6.	Ms. Suwarin Konthong	Director and Chief Financial Officer

The Company Secretary

1. Ms. Arachaporn Boonkerd

The Company's auditors from EY Office Limited

- 1. Ms. Sumesa Tangyoosuk
- 2. Ms. Svita Yotinprasert

The Chairman of the meeting, welcomed all shareholders who participated in the Annual General Meeting of Shareholders for the year 2025 and informed the meeting about the Company's information as of March 11, 2025 as follows:

1.	Registered capital	343,471,560.50	Baht
2.	Paid-up Capital	225,207,142.50	Baht
3.	Par value per share	0.50	Baht

Page 1 / 16







The Company specified the list of shareholders who had the right to attend the Annual General Meeting of Shareholders for the year 2025 on the date of 11th March 2025, following the Section 103 of the Public Limited Companies Act B.E. 2535 and Article No.40 of the Articles of Association of the Company states in the shareholders' meeting, the number of the shareholders and proxies (if any) present shall not be less than 25 people and the aggregate number of shares shall not be less than one-third of the paid-up shares, to constitute a quorum.

The number of shareholders present at the Meeting and proxies in total 28 shareholders who held 158,202,774 shares. The total shares accounted for 35.1238% percent of the Company's 450,414,285 paid-up shares, thus constituting a quorum under the Articles of Association.

The Chairman opened the Annual General Meeting of Shareholders for the year 2025 and invited Ms. Arachaporn Boonkerd, Company Secretary, to explain the rules of practice and procedure in the Meeting as follows:

Company Secretary explain the rules of practice and procedure in the Meeting that had been conducted as agendas which were shown on the notice of the Annual General Meeting for the year 2025, every shareholder has one vote per share. The Meeting had 8 agendas, and each agenda has to be voted as follows:

Ш	The Agenda no. 2, Agenda no. 4, Agenda no. 5 and Agenda no. 7 shall have the majority of votes
	from shareholders present at the meeting. If there is an equal vote, the Chairman shall cast one
	additional vote as the final vote.
	The Agenda no. 1 and Agenda no. 3 do not require casting votes because this is informative agenda.
	The Agenda No. 6 shall receive a vote of not less than two-thirds of the total number of votes and

☐ The Agenda No. 8 is the accepting agenda proposed by shareholders.

Company Secretary informed the meeting that this Annual General Meeting of Shareholders, DOD Biotech Public Company Limited shall keep, use and disclose personal information, audios, and videos of all attendants for recording and preparing the minutes of the Meeting, organizing the Meeting etc. All shareholders could read the additional details related to the Personal Data Protection as indicated in the enclosure of the Meeting's invitation letter and on the Company's website.

exclude the votes of the directors who are stakeholders in the amount of 473,100 votes.

Moreover, before casting votes on each agenda, the attendees of the Meeting shall have an opportunity to ask or express their opinions in involving agenda as appropriate. The shareholders who intend to ask or express their opinions are required to inform their name and last name to the Meeting every time. Since this meeting is held through electronic means, there are rules, voting methods, vote counting, and method to ask questions or express opinions as follows:

@ @dodbiotech





- The meeting will consider the matters in order of the agenda specified in the invitation letter.
 By presenting information for each agenda, the Company will give shareholders an opportunity to ask questions before voting and will notify the result of the vote at the meeting when the votes are counted.
- 2. For voting, choose the agenda then press the "Vote" button, the system will display a button for voting, a total of 3 buttons which is 1. Agree (Green) 2. Disagree (Red) 3. Abstain (Orange). For shareholder who has more than one proxies, the system will display all names of proxies then shareholder can vote separately for each user account.

For Cancel the vote, press the "Cancel Vote" button. For any shareholder who has not voted within the specified time. The company will assume that the shareholder agrees with that agenda. The voting can be edited until the voting results are closed. The Company allows two minutes for voting. When the voting results are closed, the result of that agenda will be announced at the meeting.

- 3. In the case of shareholders accepting proxies from many shareholders, press to "Account" button and press on the "Change Account" button to access other shareholders' accounts. The system will not remove votes from the meeting base.
- 4. In case a shareholder wishes to leave the meeting before closing the voting, shareholders' votes will not be counted as a quorum for such agenda, and the votes will not be counted immediately in the remaining agenda. However, leaving the quorum in any agenda will not disqualify the shareholders' rights or proxies to return to the meeting and vote on the next agenda in the system.
- 5. For asking questions or expressing opinions before voting for each agenda, the company will give the attendees an opportunity to ask questions or express opinions on issues related to that agenda. By select the agenda and press "Question" button, then type the question then click "Send". The company will answer questions in the meeting room on the agenda related to that question. The company reserves the right to consider selecting questions as appropriate. The attendees must inform their first and last names, and status as a shareholder or proxy before asking questions every time. That is for the company to be able to accurately and completely recorded the minutes of the meeting.





However, the company reserves the right to delete any disrespectful comments, defame others, or violate any laws including infringement of the rights of others, disturbing the meeting, or causing trouble to other attendees.

- 6. In the event that there are a large number of shareholders wishing to ask questions, to maintain the duration of the meeting, let the shareholders ask questions via message for the staff will keep that questions then answer at the end of the meeting or on the company's website.
- 7. In case of shareholders encounter problems entering the meeting system or voting system, please follow the instructions given along with the invitation letter or press "Help" button or contact Inventech Call Center and Line Official Account.
- 8. In case of the system crashes during the meeting, shareholders will receive an email to return to the meeting through the support system.

The Chairman then commenced the Meeting with the following agenda:

Agenda 1 To acknowledge the directors' report on the Company's performance for the year 2024

The Chairman of the meeting assigned Ms. Suwarin Konthong, Chief Financial Officer to present information to the Meeting.

Chief Financial Officer presented the Company's performance in 2024 to the meeting, a summary of which was as follows:

Revenue Structure

Type of Income	Year 2024		Year 2023		
Type of income	Million Baht %		Million Baht	%	
Sale Revenues					
- Beauty Products	184.69	27.90	167.48	24.18	
- Health Products	460.69	69.59	496.13	71.62	
Total Sales Revenues	645.38	97.48	663.61	95.80	
Others Income	16.65	2.52	29.09	4.20	
Total Income	662.03	100.00	692.70	100.00	





Income Statement (Consolidated Financial Statement)

(Unit : Million THB)

	2024 2023			Increase	Increase/(Decrease)	
Revenues from Sale	645.38	100.00%	663.61	100.00%	(18.23)	(2.75%)
Cost of Sales	438.57	67.96%	406.36	61.23%	32.21	7.93%
Gross Profit	206.81	32.04%	257.25	38.77%	(50.44)	(19.61%)
Selling and Distribution Expenses	90.65	14.05%	83.68	12.61%	6.97	8.33%
Administrative Expenses	118.35	18.34%	114.83	17.30%	3.52	3.07%
Operating Profit(Loss)	(2.19)	(0.34%)	58.74	8.85%	60.93	103.73%
Other Revenues	16.65	2.58%	29.09	4.38%	(12.44)	(42.76%)
Finance Income	0.73	0.11%	0.25	0.04%	0.48	192.00%
Finance Cost	3.73	0.58%	5.31	0.80%	(1.58)	(29.76%)
Other expenses	(29.03)	(4.50%)	(10.04)	(1.51%)	18.99	189.14%
Profit before income tax expenses	40.49	6.27%	92.81	13.99%	(52.32)	(56.37%)
Income tax expenses	(13.32)	(2.06%)	(28.30)	(4.26%)	14.98	(52.93%)
Profit for the year from continued operation	27.17	4.21%	64.51	9.72%	(37.34)	(57.88%)
Loss for the period from discontinued	(218.28)	(33.82%)	(58.14)	(8.76%)	160.14	275.44%
Profit(Loss) for the year	(191.11)	(29.61%)	6.37	0.96%	197.48	3,100.16%
Non-controlling interests of the subsidiaries						
Profit(Loss) for the year from continued operation	(4.48)	(0.69%)	6.38	0.96%	10.86	170.22%
Loss for the year from discontinued operation	(27.29)	(4.23%)	(7.20)	(1.08%)	20.09	279.03%
Profit(Loss) for the year attributable to Non-controlling interest	(31.77)	(4.92%)	(0.82)	(0.12%)	30.95	3,774.39%
Profit(Loss) attributable to Equity holders of the parent company	(159.34)	(24.69%)	7.19	1.08%	166.53	2,316.13%

The Statement of Financial position

(Unit : Million THB)

	As at 31 Dec	ember 2024	As at 31 Dec	ember 2023	Cha	nge
Cash and cash equivalents	223.09	17.34%	67.99	4.66%	155.10	228.12%
Trade and other receivables	42.20	3.28%	111.64	7.66%	(69.44)	(62.20%)
Inventories	126.88	9.86%	150.40	10.32%	(23.52)	(15.64%)
Other current assets	57.69	4.48%	41.92	2.88%	15.77	37.62%
Assets held for sale	166.69	12.96%	-	0.00%	166.69	100.00%
Total Current Assets	616.55	47.93%	371.95	25.52%	244.60	65.76%
Restricted bank deposits	16.43	1.28%	17.05	1.17%	(0.62)	(3.64%)
Other non-current financial assets	2.60	0.20%	2.60	0.18%	-	-
Property, plant and equipment	509.41	39.60%	862.06	59.14%	(352.65)	(40.91%)
Rights of use assets	1.92	0.15%	53.78	3.69%	(51.86)	(96.43%)
Goodwill	0.25	0.02%	0.25	0.02%	-	-
Other intangible assets	43.06	3.35%	50.48	3.46%	(7.42)	(14.70%)
Deferred tax assets	95.50	7.42%	90.64	6.22%	4.86	5.36%
Other non-current assets	0.59	0.05%	8.83	0.61%	(8.24)	(93.32%)
Total Non-Current Assets	669.76	52.07%	1,085.69	74.48%	(415.93)	(38.31%)
Total Assets	1,286.31	100.00%	1,457.64	100.00%	(171.33)	(11.75%)
	As at 31	December 20	24 As at 31 De	ecember 2023	Char	nge
Bank overdrafts and short-term loans from bar	nk 45	5.00 3.5	0% 110.4	19 7.58%	(65.49)	(59.27%)
Trade and other payables	70	0.92 5.5	51% 116.	51 7.99%	(45.59)	(39.13%)
Advance received for goods	19	9.83 1.5	4% 27.2	23 1.87%	(7.40)	(27.18%)
Deposit from sales of land, plant and equipme	ent 215	5.00 16.3	71% -	0.00%	215.00	100.00%
Current portion of long-term loans		I				
		- 0.0	0% 2.	12 0.15%	(2.12)	(100.00%)
Current portion of leases liabilities			0% 2.6 6% 2.8		(2.12) (2.03)	(100.00%) (72.50%)
Current portion of leases liabilities Income tax payable		0.0		0.19%	` 1	
·		0.77	6% 2.8	0.19% 18 1.45%	(2.03)	(72.50%)
Income tax payable Other current liabilities Liabilities directly associated with the		0.77 0.0 1.72 0.1 1.05 0.0	6% 2.8 13% 21: 8% 2.4	0.19% 18 1.45% 47 0.17%	(2.03) (19.46) (1.42)	(72.50%) (1,131.40%) (57.49%)
Income tax payable Other current liabilities Liabilities directly associated with the assets held for sale	1	0.77 0.0 1.72 0.1 1.05 0.0 1.68 0.9	2.8 13% 21: 18% 2.4 2.4	0.19% 18 1.45% 47 0.17%	(2.03) (19.46) (1.42)	(72.50%) (1,131.40%) (57.49%)
Income tax payable Other current liabilities Liabilities directly associated with the assets held for sale Total Current Liabilities	1	0.77 0.0 1.72 0.1 1.05 0.0 1.68 0.9 5.97 28.4	6% 2.8 13% 21: 8% 2.4 91% - 5% 282.8	0.19% 18 1.45% 0.17% 0.00% 0.00%	(2.03) (19.46) (1.42) 11.68 83.17	(72.50%) (1,131.40%) (57.49%) 100.00% 29.41 %
Income tax payable Other current liabilities Liabilities directly associated with the assets held for sale Total Current Liabilities Lease liabilities, net of current portion	1 365	0.77 0.0 1.72 0.1 1.05 0.0 1.68 0.9 5.97 28.4	6% 2.8 13% 21: 8% 2.4 21% - 5% 282.8 2% 53.2	0.19% 18 1.45% 0.17% 0.00% 0.00% 19.40% 28 3.66%	(2.03) (19.46) (142) 11.68 83.17 (52.99)	(72.50%) (1,131.40%) (57.49%) 100.00% 29.41% (99.46%)
Income tax payable Other current liabilities Liabilities directly associated with the assets held for sale Total Current Liabilities Lease liabilities, net of current portion Provision for long-term employee benefits	365 C	0.77	6% 2.8 13% 21: 8% 2.4 11% - 5% 282.8 2% 53.2 2% 10.3	0.00% 0.19% 1.45% 0.17% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%	(2.03) (19.46) (142) 11.68 83.17 (52.99) (0.13)	(72.50%) (1,131.40%) (57.49%) 100.00% 29.41% (99.46%) (121%)
Income tax payable Other current liabilities Liabilities directly associated with the assets held for sale Total Current Liabilities Lease liabilities, net of current portion Provision for long-term employee benefits Deferred tax liabilities	1 365 0 10	0.77 0.0 1.72 0.1 1.05 0.0 1.68 0.9 1.68 0	2.66% 2.86 13% 21: 18% 2.4 191% - 15% 282.6 20% 532 22% 10.5 184	0.019% 0.19% 1.45% 1.45% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 1.45% 0.00% 0.00% 1.45% 0.00% 0.00% 1.45% 0.00% 0	(2.03) (19.46) (1.42) 11.68 83.17 (52.99) (0.13) (7.55)	(72.50%) (1,131.40%) (57.49%) 100.00% 29.41% (99.46%) (121%) (40.83%)
Income tax payable Other current liabilities Liabilities directly associated with the assets held for sale Total Current Liabilities Lease liabilities, net of current portion Provision for long-term employee benefits Deferred tax liabilities Other non-current liabilities	1 365 0 10 10	0.77 0.0 1.72 0.1 1.05 0.0 1.68 0.9 5.97 28.4 0.29 0.0 0.59 0.8 0.94 0.8 6.60 0.9	2.66% 2.86 13% 21: 18% 2.4 191% - 15% 282.6 10.2	0.19% 18 1.45% 47 0.17% 0.00% 0.00% 19.40% 28 3.66% 72 0.74% 19 1.27% 29 0.84%	(2.03) (19.46) (1.42) 11.68 83.17 (52.99) (0.13) (7.55) (569)	(72.50%) (1,131.40%) (57.49%) 100.00% 29.41% (99.46%) (1,21%) (40.83%) (46.30%)
Income tax payable Other current liabilities Liabilities directly associated with the assets held for sale Total Current Liabilities Lease liabilities, net of current portion Provision for long-term employee benefits Deferred tax liabilities Other non-current liabilities Total Non-Current Liabilities	1 365 0 10 10 6	0.77 0.0 1.72 0.1 1.05 0.0 1.68 0.9 5.97 28.4 0.29 0.0 0.59 0.8 0.94 0.8 6.60 0.9	2.66% 2.86 13% 21: 18% 2.4 191% - 15% 282.6 10.2 15% 18.4 15% 12.2 10.3 10.	0.19% 145% 47 0.17% 0.00% 0.00% 1940% 28 3.66% 72 0.74% 19 1.27% 19 0.84%	(2.03) (19.46) (1.42) 11.68 83.17 (52.99) (0.13) (7.55) (569)	(72.50%) (1,131.40%) (57.49%) 100.00% 29.41% (99.46%) (1,21%) (40.83%) (46.30%) (70.01%)
Income tax payable Other current liabilities Liabilities directly associated with the assets held for sale Total Current Liabilities Lease liabilities, net of current portion Provision for long-term employee benefits Deferred tax liabilities Other non-current liabilities	1 365 0 10 10 6 28	0.77 0.0 1.72 0.1 1.05 0.0 1.68 0.9 5.97 28.4 0.29 0.0 0.59 0.8 0.94 0.8 6.60 0.9	2.6% 2.8 13% 21: 18% 2.4 191% - 15% 282.6 10.2 15% 18.4 15% 12.2 10.3 15% 18.4 12.5 14.5 15% 18.4 16% 377.5	0.19% 145% 47 0.17% 0.00% 0.00% 1940% 28 3.66% 72 0.74% 19 1.27% 19 0.84% 650% 88 25.90%	(2.03) (19.46) (1.42) 11.68 83.17 (52.99) (0.13) (7.55) (569)	(72.50%) (1,131.40%) (57.49%) 100.00% 29.41% (99.46%) (1,21%) (40.83%) (46.30%)





For the year of 2024, The Company had the Revenue from Sale of THB 645.38 Million which was decrease by THB 18.23 Million or 2.75% compared with the same period of 2023 because the company have changed the customer base for diversified the market risk.

The Company had profit (loss) from continued operation amount of THB 27.17 Million, which was decrease by THB 37.34 million or 57.88% due to the provision for remaining inventory that has resolved to cease operations If these item are adjusted out because they are one-time expenses, the Company will have a normalized profit (loss) for the period from continued operating amount of THB 57.73 Million.

For the year of 2024, the Company had loss from discontinued operation by THB 218.28 Million, which increased compared with the same period of 2023 by THB 58.14 Million due to the two subsidiaries business discontinued operation.

The Company has the profit (loss) attributable to equity holders of the parent company by THB (159.34) Million, while in the same period of last year has the loss attributable to equity holders of the parent company by THB 7.19 Million, which was increased THB 166.53 Million or 2,316.13%, which mainly came from the provision for remaining inventory and the provision of a subsidiary company that has resolved to cease operations.

As of December 31, 2024, the total assets were decrease by THB 171.33 Million or 11.75% compared with December 31, 2023, consisted of cash and cash equivalents increased by THB 155.10 Million, an increase from receiving deposits from sales and some land, buildings and equipment during the period, trade and other receivables decreased by THB 69.44 Million due to better management of debtors, assets held for sale increased by THB 166.69 Million came from a subsidiary company entered into an agreement to purchase and sell assets and received a partial deposit during the period. Property, plant and equipment decreased by THB 352.65 Million due to the periodic depreciation and sold investments in Siam Herbal Tech Company Limited during the period as well as another part is classified as assets held for sale, in amount of THB 166.69 Million, and rights of use assets decreased by THB 51.86 Million due to the sale of investment in Siam Herbal Tech Co., Ltd. during the period.

As of December 31, 2024, the total liabilities and shareholder's equity were decrease by THB 171.33 Million or 11.75% compared with December 31, 2023, which mainly to repayment of bank overdrafts and short-term loans from banks amount of THB 65.49 Million, trade accounts payable and other payables decreased by THB 45.59 Million from the payment of debts due, deposits received from the sale of land, buildings and equipment increased by THB 215 Million





because a subsidiary entered into an agreement to purchase and sell assets and received some deposits during the period, payment of corporate income tax amount of THB 19.46 Million, and Lease liabilities decreased by THB 52.99 Million due to the sale of investment in Siam Herbal Tech Co., Ltd. during the period.

In conclusion, with the continuous restructuring of the business by terminating the operations of subsidiaries that have consistently incurred losses, the company has begun to have normalized operating profit and profit for the period from continued including has proceeded with the sale of assets of discontinued subsidiaries in order to increase liquidity for investment in improving production efficiency, leading to sustain competitive advantage.

Miss Arachaporn Boonkerd, Company Secretary then provided shareholders with an opportunity to ask questions and/or give opinions. In this agenda, there are no and/or give opinions from the shareholders.

As this agenda item was for acknowledgment the Company's performance for the year 2024, there was no resolution to be adopted.

Agenda 2 To consider approving the Company's audited the financial statements for the year ended December 31, 2024.

The Chairman of the Meeting assigned Mr. Dusit Chongsutthanamanee, Chairman of Audit Committee proposed that the meeting consider and approve the financial statements for the year ended December 31, 2024, which have been audited by the certified public accountant from EY Office Limited. The auditor has expressed the opinion that the statement of financial position as of December 31, 2024, as well as the statement of comprehensive income and statement of cash flows for the same period, are fairly presented in all material respects in accordance with financial reporting standards. A summary of the details is as follows:

Statement of Financial Position (Consolidated financial statements) in Brief

Statement of	2024		20	23	Change	
Financial Position	Million Baht	%	Million Baht	%	Million Baht	%
Assets	1,286.31	100.00%	1,457.64	100.00%	(171.33)	11.75%
Liabilities	394.39	30.66%	377.58	25.90%	16.81	4.45%
Shareholder's Equity	891.92	69.34%	1,080.06	74.10%	(188.14)	(17.42%)





As of December 31, 2024, the total assets were decrease by THB 171.33 Million or 11.75% compared with December 31, 2023, due to the sale of investment in Siam Herbal Tech Co., Ltd. during the period.

As of December 31, 2024, the total liabilities were increased by THB 16.81 Million or 4.45% rise due to a subsidiary entered into an agreement to purchase and sell assets and received some deposits during the period, Meanwhile, total shareholders' equity decreased by THB 188.14 Million or 17.42%, mainly due to the previously mentioned losses incurred by the parent company.

Income Statement (Consolidated) in Brief

(Unit: Million THB)

Statement	2024	2023	Change		
Statement	2024	2023	Million Baht	%	
Sales Revenues	645.38	663.61	(18.23)	(2.75%)	
Cost of Sale	438.57	406.36	32.21	7.93%	
Gross Profit	206.81	257.25	(50.44)	19.61%	
Selling Expenses	90.65	83.68	6.97	8.33%	
Administrative Expense	118.35	114.83	3.52	3.07%	
Operating Profit (Loss)	(2.19)	58.74	60.93	103.73%	
Profit (Loss) attributable to shareholders of the parent	(159.34)	7.19	166.53	2,316.13%	

For the operating result in 2024 compared to 2023, the Company had the Revenue from Sale of THB 645.38 Million, which was decrease by THB 18.23 Million or 2.75% and operating profit (loss) of THB (2.19) Million, which was decrease by THB 60.93 Million or 103.73%. When it was adjusted for other items, as a result the profit (loss) attributable to Equity holders of the parent company by THB (159.34) Million, compared to a net profit of THB 7.19 Million in the same period of the previous year.

Miss Arachaporn Boonkerd, Company Secretary then provided shareholders with an opportunity to ask questions and/or give opinions. In this agenda, the shareholders raised the following additional inquiries:





Question 1: Mr. Wuttisak Udompornphadung, a shareholder, inquired about the impairment provision set by the company, PCCA Laboratory Company Limited, asking how much impairment has been recognized and also about the sale of the factory land valued at 215 million baht, and how much profit can be recognized from the sale.

Answer 1: Mr. Dusit Chongsutthanamanee, Vice Chairman of the Board, explained that PCCA Laboratory Company Limited has two properties. One is a factory located in Chonburi Province, which has already been sold, however, the exact profit amount cannot be determined yet. It is expected that the profit will be recorded in Q1/2025. The second property is an office building located in Bangkok, which remains in use. Any future decision to sell this property will be disclosed to shareholders accordingly.

Ms. Suwarin Kornthong, Chief Financial Officer, further explained that, as of December 31, 2024, the separate financial statements recorded an impairment provision of 32 million bath for PCCA Laboratory Company Limited, with the book value of assets approximately 139 million baht. Part of the asset, specifically the factory, has already been sold.

Question 2: Mr. Wuttisak Udompornphadung, a shareholder, asked the company about its plans to manage the high cash and liquidity resulting from the sale of assets, and how the company intends to use these funds.

Answer 2: Mr. Dusit Chongsutthanamanee, Vice Chairman of the Board, explained that the Company has an ongoing business expansion plan focusing on enhancing production capacity and investing in modern machinery and equipment to support future growth. Additionally, part of the funds will be used as working capital to support increasing sales volume.

Question 3: Mr. Wuttisak Udompornphadung, a shareholder, inquired about VAT refund of 14 million baht submitted by Siam Herbal Tech Company Limited, asking when the company expects to receive the refund.

Answer 3: Ms. Suwarin Kornthong, Chief Financial Officer, explained that Siam Herbal Tech Company Limited is in the process of submitting relevant documents to the Revenue Department. The case is currently under review by the department, and the exact timeframe for receiving the refund cannot be determined at this stage.





Question 4: Mr. Wuttisak Udompornphadung, a shareholder, asked whether the company plans to make additional impairment provisions in the future.

Answer 4: Mr. Dusit Chongsutthanamanee, Vice Chairman of the Board, that the Company currently focuses on two core businesses. The first is the manufacturing business, for which no additional impairment has been recognized for machinery, land, buildings, or equipment. The second is Auswelllife Company Limited, a subsidiary whose main assets consist of inventory that is considered current and circulating. There is currently no necessity to recognize further impairments. For other subsidiaries, the Company believes that all necessary impairment provisions have already been adequately recorded.

There being no further questions or comments from the shareholders,

Company Secretary requested shareholders to adopt a resolution approving the Company's audited the financial statements for the year ended December 31, 2024.

The voting results were as follows:

Abstained	0	Votes	Equivalent to	0.0000
Total	158,202,774	Votes	Equivalent to	100.0000
Disapproved	0	Votes	Equivalent to	0.0000
Approved	158,202,774	Votes	Equivalent to	100.0000

The meeting's resolution: With the majority votes of the shareholders who were present at the meeting and casted their votes, the meeting passed the resolution approving the Audited Statement of Financial Position and Income Statement for the year ended 31 December 2023 as proposed in all respects.

Agenda 3 To consider and acknowledge the omission of dividend payments for the year 2024

The Chairman of the Meeting assigned Mr. Dusit Chongsutthanamanee, Vice Chairman reported that the company's dividend payment policy stipulates that dividends shall be paid at a rate of no less than 50% of the net profit after deducting corporate income tax and all legally required reserves (if any). However, for the year 2024, the company incurred a net loss of 295,936,315 baht, as reflected in the separate financial statements. Therefore, the Board of





Directors deems it appropriate to propose to the Annual General Meeting of Shareholders for acknowledgment of the omission of the dividend payment for the year 2024.

Miss Arachaporn Boonkerd, Company Secretary then provided shareholders with an opportunity to ask questions and/or give opinions. In this agenda, there are no and/or give opinions from the shareholders.

As this agenda item was for acknowledgment the omission of dividend payments for the year 2024, there was no resolution to be adopted.

Agenda 4 To consideration and approval of Transferring share premium to Offset Accumulated Company Losses

The Chairman of the Meeting assigned Mr. Dusit Chongsutthanamanee, Vice Chairman reported presented to the meeting that the share premium has detail as below:

Statement	Amount (Baht)
Deficits as at 31 December 2023	(295,936,315)
Transfer share premium to compensate the deficits	295,936,315
Share premium	651,330,110

Miss Arachaporn Boonkerd, Company Secretary then provided shareholders with an opportunity to ask questions and/or give opinions. In this agenda, there are no and/or give opinions from the shareholders.

Company Secretary requested shareholders to adopt a resolution approving the transfer of share premium in the amount of 295,936,315 Baht to offset the accumulated losses of the Company.

The voting results were as follows:

Approved	158,202,774	Votes	Equivalent to	100.0000
Disapproved	0	Votes	Equivalent to	0.0000
Total	158,202,774	Votes	Equivalent to	100.0000
Abstained	0	Votes	Equivalent to	0.0000



DOD BIOTECH

111 Moo 2 Tumbol Thachin, Amphur Muang Samutsakhon Samutsakhon 74000

The meeting's resolution: With the majority votes of the shareholders who were present at the meeting and casted their votes, the meeting passed the resolution approving the transfer of share premium in the amount of 295,936,315 Baht to offset the accumulated losses of the Company as proposed in all respects.

Agenda 5 To consider and approve the appointment of the directors those retired by rotation to re-

elect the aforementioned to be the Company's director for another term.

The Chairman of the Meeting assigned Mr. Dusit Chongsutthanamanee, Chairman of the Nomination and Remuneration Committee informed that Article 22 of the Company's Articles of Association stipulates that 1/3 of the total number of directors shall retire from the company. The shareholders can re-appoint the directors who have completed their term for re-entry. Therefore, 1/3 of the total 6 directors of the Company are 2 people who must retire by rotation at the annual general meeting of shareholders every year. Therefore, it must be proposed to the shareholders to consider appointing directors to replace those who are due to retire by rotation, namely 1. Mr. Porntep Siriwanarangsun and 2. Mr. Torlarp Chaiyachao shall be reelected for another term.

The Nomination and Remuneration Committee considered the 2 directors to have the necessary qualifications as per the Public Limited Companies Act B.E.2535 and relevant knowledge, including valuable experience that can help the operations of the Company. Hence, the Nomination and Remuneration Committee deemed it appropriate to propose the reappointment of the Company's directors in place of the directors who are retired by rotation. The profile of the 2 directors shown on the attachment No.5.

Miss Arachaporn Boonkerd, Company Secretary then provided shareholders with an opportunity to ask questions and/or give opinions. In this agenda, there are no and/or give opinions from the shareholders.

Company Secretary requested shareholders to adopt a resolution approving the appointment of the directors those retired by rotation to re-elect the aforementioned to be the Company's director for another term.

The voting results were as follows:





1. Mr. Porntep Siriwanarangsun:

Approved	158,202,774	Votes	Equivalent to	100.0000
Disapproved	0	Votes	Equivalent to	0.0000
Total	158,202,774	Votes	Equivalent to	100.0000
Abstained	0	Votes	Equivalent to	0.0000
2. Mr. Torlarp Chaiyachao:				
Approved	158,202,774	Votes	Equivalent to	100.0000
Disapproved	0	Votes	Equivalent to	0.0000
Total	158,202,774	Votes	Equivalent to	100.0000
Abstained	0	Votes	Equivalent to	0.0000

The meeting's resolution: With the majority votes of the shareholders who attended the meeting and casted their votes, the meeting passed the resolutions re-electing the 2 candidates as Directors in replacement of the ones retiring by rotation as proposed in all respects.

Agenda 6 To approve the fixing of the director's remuneration for the year 2025

The Chairman of the Meeting assigned Mr. Dusit Chongsutthanamanee, Chairman of the Nomination and Remuneration Committee informed that the Board of Directors agreed with the regulation on the remuneration of the Company, proposed by the Nomination and Remuneration Committee. The regulation on remuneration considers duty, responsibility, achievement, and interest received from each director, and the financial amount in the year 2025 is limited is not exceeding Baht 5.0 million that amount is the same as last year from shareholders' approval.

For vote-counting of this agenda, the votes of directors who are stakeholders have no right to vote, with a total shareholding of 473,100 votes, which does not count as the base of votes in the vote-counting. In this agenda, a resolution must be passed with a vote of not less than two-thirds of the total number of votes of the shareholders attending the meeting according to the Public Act, Section 90.

Miss Arachaporn Boonkerd, Company Secretary then provided shareholders with an opportunity to ask questions and/or give opinions. In this agenda, there are no and/or give opinions from the shareholders.





Company Secretary requested shareholders to adopt a resolution approving the appointment of the director's remuneration for the year 2025.

The voting results were as follows:

Approved	157,557,874	Votes	Equivalent to	99.8910
Disapproved	0	Votes	Equivalent to	0.0000
Abstained	171,800	Votes	Equivalent to	0.1089
Total	157,729,674	Votes	Equivalent to	100.0000
Not entitled to vote	473,100	Votes		

The meeting's resolution: With a majority of more than two-thirds of the votes of the shareholders who were present at the meeting, the meeting adopted a resolution approving the fixing of the director's remuneration for the year 2025 as proposed in all respects.

Agenda 7 To approve the appointment of the auditors and fixing the audit fee for the year 2025

The Chairman of the Meeting assigned Mr. Dusit Chongsutthanamanee, Chairman of Audit Committee informed the meeting that the Audit Committee has a process for selecting auditors for the year 2025 and proposes to the Board of Directors for consideration and proposals to the shareholders' meeting for appointment.

1. Mrs. Phoonnard Phaocharean	Certified Public Accountant no. 5238
2. Ms. Manee Rattanabunnakit	Certified Public Accountant no. 5313
3. Ms. Sineenart Jirachaikhuankhan	Certified Public Accountant no. 6287
4. Ms. Sumesa Tangyoosuk	Certified Public Accountant no. 7627

From EY Office Limited is the Company's accountant for the year 2025, with the Audit Committee's opinion that EY Office Co., Ltd. has a comprehensive network that is recognized in many countries. This will make the auditing standard of the company international and all 4 auditors, including EY Office Company Limited, have no relationship or transaction that may cause a conflict of interest. The audit fees proposed in 2025 are determined in the amount not exceeding Baht 2.5 million.

Miss Arachaporn Boonkerd, Company Secretary then provided shareholders with an opportunity to ask questions and/or give opinions. In this agenda, there are no and/or give opinions from the shareholders.

Page 14 / 16





Company Secretary requested shareholders to adopt a resolution approving the appointment of the auditors and fixing the audit fee for the year 2025.

The voting results were as follows:

Approved	158,202,774	Votes	Equivalent to	100.0000
Disapproved	0	Votes	Equivalent to	0.0000
Total	158,202,774	Votes	Equivalent to	100.0000
Abstained	0	Votes	Equivalent to	0.0000

The meeting's resolution: With the majority votes of the shareholders who were present at the meeting and casted their votes, the meeting passed the resolution approving appointment of the auditors and fixing the audit fee for the year 2025 as proposed in all respects.

Agenda 8 Other businesses (if any).

The Chairman of the Meeting assigned Miss Arachaporn Boonkerd, Company Secretary, to present information to the Meeting.

Company Secretary informed the meeting that Section 105 of the Public Limited Companies Act B.E. 2535 states that "the shareholders holding the aggregate number of shares of not less than one-third of the total number of shares sold may request the consideration at the meeting of other business in addition to that specified in the notice summoning the meeting" Therefore, there is an agenda 8 as stipulated by law.

Company Secretary then provided shareholders with an opportunity to ask questions and/or give opinions. In this agenda, the shareholders raised the following additional inquiries:

Question 1: Mr. Wuttisak Udompornphadung, a shareholder, inquired about the types of businesses operated by the subsidiaries DOD Infinite Company Limited and A Metaverse Company Limited, and asked about their revenues and net profits for 2024.

Answer 1: Ms. Suwarin Kornthong, Chief Financial Officer, explained that DOD Infinite Company Limited operates as an investment company that invests in subsidiaries. In 2024, it generated revenue of 15 million baht and a net profit of 15 million baht. A Metaverse





Company Limited engages in the distribution of dietary supplements and reported revenue of 30 million baht with a net loss of 5 million baht.

Question 2: Mr. Wuttisak Udompornphadung, a shareholder, inquired about the company's business outlook for 2025, market competition, whether new customers are being acquired, whether existing customers are making repeat orders, credit terms and debt collection policies, and strategies to increase revenue, sales, profit, and dividends for shareholders.

Answer 2: Mr. Torlarp Chaiyachow, Acting Chief Executive Officer, explained that the Company is aware of the intense competition within the industry. As a result, it focuses on retaining key customers while also expanding its new customer base, which continues to show steady growth. Existing customers also consistently place repeat orders, reflecting confidence in the quality of the Company's products and services. The Company grants credit only to customers who pass strict financial risk assessments and has a dedicated debt management team to closely monitor collections and maintain an appropriate level of bad debt. To boost revenue, the Company has invested in new technology and machinery to enhance production efficiency and strictly control costs, thereby improving sustainable profitability. Furthermore, the Company is committed to achieving strong financial performance that enables it to pay dividends to shareholders in the future, subject to net profit and overall financial standing.

There being no further questions or comments from the shareholders,

The Chairman thanked the shareholders for taking the time to attend the meeting and declared the meeting closed.

The meeting was closed at 16:00 hours.

Note: The voting scores reported in this meeting do not correspond to those announced in the meeting due to an increase in the number of shareholders during each agenda item.

Signed

----- Signature-----

Chairman of The Meeting

(Mrs. Arpaporn Kosolkul) Chairman

BI®TECH LE

Miss Arachaporn Boonkerd
Company Secretary/ Minute's recorder

Page 16 / 16

∯ @(

@ @dodbiotech